GSK's Jemperli shows survival benefits in phase III trial for endometrial cancer

  • Investing.com
  • Stock Market News
GSK's Jemperli shows survival benefits in phase III trial for endometrial cancer
Credit: © Reuters.

GSK plc's Jemperli (dostarlimab), in combination with standard chemotherapy, has shown a statistically significant and clinically meaningful benefit in a phase III RUBY trial involving adult patients with advanced or recurrent endometrial cancer. The trial is the first to demonstrate a survival benefit under such conditions, according to Hesham Abdullah, GSK's global Oncology head.

The RUBY trial involved the administration of Jemperli plus carboplatin and paclitaxel, followed by Jemperli as a monotherapy, against placebo plus chemotherapy. It reached its primary endpoint of overall survival, showing significant benefit for all patients and prespecified subgroups (dMMR/MSI-H and MMRp/MSS).

Prior to this, the RUBY trial had also met its other primary endpoint of progression-free survival (PFS), demonstrating a 72% and 36% risk reduction in disease progression or death. These PFS results have led to approvals for Jemperli for certain endometrial cancer patient subsets.

Following an FDA-approved test, Jemperli gained FDA approval in July 2023 and UK approval in October 2023 for use with platinum-containing chemotherapy in systemic therapy candidates with dMMR/MSI-H endometrial cancer. Its application is currently under review in the EU, Australia, Canada, Switzerland, and Singapore.

Endometrial cancer, which originates from the uterus' inner lining, is predominant in developed nations and registers approximately 417,000 new cases annually.

Early Monday saw GSK's stock at 1,443.10 pence, marking a 0.7% rise. The company's stock has also shown a year-on-year growth of 1.0%.

InvestingPro Insights

In light of GSK's recent success with Jemperli, it's worth taking a look at some key data and tips from InvestingPro.

Firstly, GSK has a market capitalization of 70.95 billion USD, which demonstrates its significant presence in the pharmaceutical industry. The company also has a P/E ratio of 3.79, which could be an attractive figure for potential investors.

In terms of growth, GSK has seen a revenue growth of 5.43% over the last twelve months as of Q2 2023, indicating a steady increase in its financial health.

InvestingPro Tips highlight that GSK yields a high return on invested capital and has maintained dividend payments for 23 consecutive years. This suggests that the company is not only profitable but also consistently returns value to its shareholders.

Lastly, GSK's stock generally trades with low price volatility, which may be appealing to investors looking for a more stable investment.

For more detailed information and additional tips, you can visit the InvestingPro page for GSK. With InvestingPro, you can access over 11 additional tips and metrics to help you make informed investment decisions. To learn more about our pricing, visit InvestingPro Pricing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles